Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,552.84
(
-0.43%
)
US TECH 100
23,384.00
(
-0.58%
)
Dow Jones
46,108.34
(
-0.22%
)
Brent Oil
100.18
(
3.50%
)
Bitcoin
69,273.00
(
-2.30%
)
News Focus
News Focus
Post# of 257275
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 28
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: DewDiligence post# 165254

Wednesday, 08/14/2013 8:46:27 AM

Wednesday, August 14, 2013 8:46:27 AM

Post# of 257275

In order for that sales level to be attained, GSK will have to promote the use of Tivacay with Truvada rather than with GSK’s own Epzicom.

Seems that GSK by developing its own single tablet regimen (572-Trii) containing Tivacay and Epzicom is aiming to compete with Stribild, although I agree - abacavir is a big disadvantage.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today